Pharmaxis gains marketing approval for cystic fibrosis therapy in Europe
The company developed Bronchitol to aid clear the airways of CF patients. Pharmaxis CEO Alan Robertson said that patients living with cystic fibrosis in Europe will now be
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The products include low particulate carboys and bottles, manufactured from resins approved for medical applications, to store and transport biopharmaceuticals, culture media, bulk vaccines and other biotech materials.